SPMS
MCID: SCN036
MIFTS: 49

Secondary Progressive Multiple Sclerosis (SPMS) malady

Categories: Neuronal diseases, Genetic diseases

Aliases & Classifications for Secondary Progressive Multiple Sclerosis

Aliases & Descriptions for Secondary Progressive Multiple Sclerosis:

Name: Secondary Progressive Multiple Sclerosis 12 52 14
Multiple Sclerosis, Secondary Progressive 69
Multiple Sclerosis, Chronic Progressive 42
Secondary-Progressive Ms 12
Spms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050783
MeSH 42 D020528
SNOMED-CT 64 425500002
UMLS 69 C0751965

Summaries for Secondary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterised by a worsening of disability, rather than by relapses followed by recovery, which progressively worsens until a steady progression of disability replaces the cycles of attacks.

MalaCards based summary : Secondary Progressive Multiple Sclerosis, also known as multiple sclerosis, secondary progressive, is related to scapuloperoneal myopathy, x-linked dominant and maturity-onset diabetes of the young. An important gene associated with Secondary Progressive Multiple Sclerosis is MBP (Myelin Basic Protein), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and t cells, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Secondary Progressive Multiple Sclerosis

Diseases in the Primary Progressive Multiple Sclerosis family:

Multiple Sclerosis 4 Multiple Sclerosis 3
Multiple Sclerosis 2 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis

Diseases related to Secondary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
id Related Disease Score Top Affiliating Genes
1 scapuloperoneal myopathy, x-linked dominant 11.1
2 maturity-onset diabetes of the young 10.3 CD40LG IL10
3 leukoencephalopathy palmoplantar keratoderma 10.3 MMP9 S100B
4 glycogen storage disease due to glucose-6-phosphatase deficiency 10.3 CCR3 CXCR3
5 spinal polio 10.3 CD40LG MBP
6 trichomalacia 10.2 IL10 MBP MMP9
7 chronic duodenal ileus 10.2 CD40LG MBP
8 unilateral hypoactive labyrinth 10.2 IL10 MMP9 S100B
9 urea cycle disorder 10.2 IL10 MBP S100B
10 t-cell prolymphocytic leukemia 10.2 CCR5 CXCR3
11 breast reconstruction 10.2 IL10 MBP S100B
12 alopecia-intellectual disability syndrome 10.2 CXCL10 MBP
13 amyotrohpic lateral sclerosis type 22 10.2 CD40LG CXCL10
14 tubular renal disease-cardiomyopathy syndrome 10.2 IL10 IL4
15 neonatal hypoxic and ischemic brain injury 10.2 IL10 MMP9
16 mucolipidoses 10.2 CD40LG S100B
17 pseudohypoaldosteronism, type iic 10.2 CD40LG CXCL10 CXCR3
18 argentine hemorrhagic fever 10.2 CCR5 CXCL10 IL10
19 lagophthalmos 10.1 IL10 IL4
20 benjamin syndrome 10.1 CD40LG CXCL10 MBP
21 infancy electroclinical syndrome 10.1 CCL2 IL10 MMP9
22 breast apocrine carcinoma in situ 10.1 CCL2 CXCR3 IL10
23 ectropion 10.1 CXCR3 IL4 MMP9
24 ceroid lipofuscinosis, neuronal, 3 10.1 IL10 IL4
25 visceral steatosis 10.1 CXCR3 IL4 MMP9
26 optic nerve hypoplasia 10.1 CCL2 IL10 MMP9
27 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 10.1 CCL2 IL10 MMP9
28 atrophy of prostate 10.1 CCL2 CD40LG IL10
29 pick disease 10.1
30 niemann-pick disease 10.1
31 diabetic angiopathy 10.1 CD40LG IL10 IL4
32 congenital hypothyroidism 10.1 CD40LG IL10 IL4
33 interval angle-closure glaucoma 10.1 CCL2 CCR2
34 indian plum allergy 10.1 CXCL10 IL10 IL4
35 lung combined large cell neuroendocrine carcinoma 10.1 CD40LG IL10 IL4
36 type 2 papillary adenoma of the kidney 10.1 CD40LG IL10 IL4
37 actinic keratosis 10.0 CD40LG IL10 IL4
38 xanthogranulomatous cholecystitis 10.0 CD40LG IL10 IL4
39 conidiobolomycosis 10.0 IL10 IL4
40 cyclosporiasis 10.0 CXCR3 IFNG IL10
41 intratubular embryonal carcinoma 10.0 CCL2 IL10 MMP9
42 persistent mullerian duct syndrome 10.0 IFNB1 IL10 MBP MMP9 S100B
43 childhood choriocarcinoma of the testis 10.0 CD40LG IL10 IL4
44 coarctation of aorta 10.0 CCR3 CXCL10 CXCR3
45 benign eccrine breast spiradenoma 10.0 CXCR3 IFNG IL10
46 von economo's disease 10.0 IFNB1 IFNG MBP
47 spontaneous ocular nystagmus 10.0 CCR3 IL10 IL4
48 bladder signet ring cell adenocarcinoma 10.0 CCL2 CXCL10 IL10 MBP
49 conduct disorder 10.0 CD40LG IFNG IL10
50 pancreatic signet ring cell adenocarcinoma 10.0 CD40LG IFNG IL10

Graphical network of the top 20 diseases related to Secondary Progressive Multiple Sclerosis:



Diseases related to Secondary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Secondary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Secondary Progressive Multiple Sclerosis:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.31 MBP MMP9 S100B CCR2 CCR3 CCR5
2 hematopoietic system MP:0005397 10.29 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
3 immune system MP:0005387 10.29 CXCR3 IFNB1 IFNG IL10 IL4 MBP
4 cellular MP:0005384 10.28 CCR2 CCR3 CCR5 CD40LG CXCL10 CXCR3
5 mortality/aging MP:0010768 10.16 CCR2 CCR5 CD40LG CXCL10 CXCR3 IFNG
6 cardiovascular system MP:0005385 10.15 CCR2 CCR5 CD40LG CXCL10 CXCR3 IFNG
7 nervous system MP:0003631 10.1 IL10 IL4 MBP MMP9 CCR2 CCR5
8 digestive/alimentary MP:0005381 10 IFNG IL10 IL4 MMP9 CCR2 CCR5
9 neoplasm MP:0002006 9.98 CCR2 CCR5 CXCR3 IFNB1 IFNG IL10
10 normal MP:0002873 9.87 CXCR3 IFNB1 IFNG IL10 IL4 MBP
11 no phenotypic analysis MP:0003012 9.85 CCR2 CCR5 IFNB1 IFNG IL10 IL4
12 renal/urinary system MP:0005367 9.73 CXCR3 IFNG IL4 MMP9 CCR2 CD40LG
13 reproductive system MP:0005389 9.7 CCR5 CD40LG IFNG IL10 IL4 MBP
14 respiratory system MP:0005388 9.5 CCR2 CCR3 CXCR3 IFNG IL10 IL4
15 vision/eye MP:0005391 9.17 CCR2 CCR5 IFNG IL10 IL4 MBP

Drugs & Therapeutics for Secondary Progressive Multiple Sclerosis

Drugs for Secondary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 250)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 4 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4 24280-93-1 446541
5
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
6
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
7
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
8
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
9
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2 624-49-7 637568 5271565
10
Interferon beta-1a Approved, Investigational Phase 4,Phase 2 145258-61-3 6438354
11
Mitoxantrone Approved, Investigational Phase 4,Phase 3 65271-80-9 4212
12
4-Aminopyridine Approved Phase 4,Phase 3 504-24-5 1727
13
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
14
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
15
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
16
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
17 Anti-Bacterial Agents Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Antifungal Agents Phase 4
20 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
21 Calcineurin Inhibitors Phase 4,Phase 2
22 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
24 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
25 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
26 Interferon-beta Phase 4,Phase 3,Phase 2,Phase 1
27 interferons Phase 4,Phase 3,Phase 2,Phase 1
28 Analgesics Phase 4,Phase 3,Phase 1,Phase 2
29 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
30 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
31 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Topoisomerase Inhibitors Phase 4,Phase 3
33 Fingolimod Hydrochloride Phase 4,Phase 3
34 Potassium Channel Blockers Phase 4,Phase 3
35 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
36 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
37 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
38 Hormones Phase 4,Phase 3,Phase 2,Phase 1
39 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
40 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
41 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
43 Methylprednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
44 Methylprednisolone Hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
45 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
46 Prednisolone acetate Phase 4,Phase 3,Phase 2,Phase 1
47 Prednisolone hemisuccinate Phase 4,Phase 3,Phase 2,Phase 1
48 Prednisolone phosphate Phase 4,Phase 3,Phase 2,Phase 1
49 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
50
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907

Interventional clinical trials:

(show top 50) (show all 166)
id Name Status NCT ID Phase
1 Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal Unknown status NCT00896012 Phase 4
2 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4
3 Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS Completed NCT00463710 Phase 4
4 Open-Label Safety Extension Study of Avonex Completed NCT00915460 Phase 4
5 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
6 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4
7 Long-term Follow-up of Fingolimod Phase II Study Patients Completed NCT02307838 Phase 4
8 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Active, not recruiting NCT02208050 Phase 4
9 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Active, not recruiting NCT03092544 Phase 4
10 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4
11 Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Terminated NCT01701856 Phase 4
12 Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple Sclerosis Terminated NCT01490840 Phase 4
13 The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis Unknown status NCT01743664 Phase 3
14 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3
15 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3
16 Sunphenon in Progressive Forms of Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3
17 FTY720 in Patients With Primary Progressive Multiple Sclerosis Completed NCT00731692 Phase 3
18 A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis Completed NCT00087529 Phase 2, Phase 3
19 A Study for Patients With Secondary Progressive Multiple Sclerosis Completed NCT00869726 Phase 2, Phase 3
20 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3
21 Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity Completed NCT01538225 Phase 3
22 Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis Completed NCT00134563 Phase 3
23 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Recruiting NCT02688985 Phase 3
24 Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND) Recruiting NCT01665144 Phase 3
25 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Recruiting NCT01433497 Phase 2, Phase 3
26 A Task-oriented Circuit Training in Multiple Sclerosis Recruiting NCT02421744 Phase 3
27 A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Active, not recruiting NCT01194570 Phase 3
28 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3
29 Effects of Acthar on Recovery From Cognitive Relapses in MS Enrolling by invitation NCT02290444 Phase 3
30 A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Not yet recruiting NCT02057159 Phase 2, Phase 3
31 Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome Not yet recruiting NCT03122652 Phase 3
32 Hydroxyurea in Primary Progressive Multiple Sclerosis Terminated NCT01103583 Phase 2, Phase 3
33 Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3
34 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3
35 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3
36 Study Evaluating Mitoxantrone in Multiple Sclerosis Terminated NCT00146159 Phase 3
37 A Study for Patients With Multiple Sclerosis Terminated NCT00870155 Phase 2, Phase 3
38 Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS) Withdrawn NCT00313976 Phase 3
39 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2
40 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2
41 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
42 Mesenchymal Stem Cells for the Treatment of MS Unknown status NCT00781872 Phase 1, Phase 2
43 The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis Unknown status NCT01144117 Phase 2
44 Combination Therapy of Betaseron-Prograf in Multiple Sclerosis Unknown status NCT00298662 Phase 2
45 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
46 Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis Unknown status NCT01569958 Phase 2
47 Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis Completed NCT01191996 Phase 1, Phase 2
48 Natalizumab Treatment of Progressive Multiple Sclerosis Completed NCT01077466 Phase 2
49 Immunological Mechanisms of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Completed NCT00342134 Phase 2
50 Masitinib in Patients With Primary Progressive Multiple Sclerosis (PPMS) or Relapse-free Secondary Progressive Multiple Sclerosis (SPMS) Completed NCT01450488 Phase 2

Search NIH Clinical Center for Secondary Progressive Multiple Sclerosis

Cochrane evidence based reviews: multiple sclerosis, chronic progressive

Genetic Tests for Secondary Progressive Multiple Sclerosis

Anatomical Context for Secondary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Secondary Progressive Multiple Sclerosis:

39
Brain, B Cells, T Cells, Cortex, Myeloid, Thyroid

Publications for Secondary Progressive Multiple Sclerosis

Articles related to Secondary Progressive Multiple Sclerosis:

(show top 50) (show all 95)
id Title Authors Year
1
Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis. ( 28045953 )
2017
2
Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? ( 27753181 )
2017
3
Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient. ( 27430119 )
2016
4
The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients. ( 27507559 )
2016
5
Brain perfusion imaging with voxel-based analysis in secondary progressive multiple sclerosis patients with a moderate to severe stage of disease: a boon for the workforce. ( 27229156 )
2016
6
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. ( 26788129 )
2016
7
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. ( 26943959 )
2016
8
Correction to: The role of MRI in the evaluation of secondary progressive multiple sclerosis. ( 27032440 )
2016
9
Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study. ( 27636543 )
2016
10
Immunotherapy Improves Cognitive Function in Secondary Progressive Multiple Sclerosis. ( 27739247 )
2016
11
RORI^t Expression and Lymphoid Neogenesis in the Brain of Patients with Secondary Progressive Multiple Sclerosis. ( 27413074 )
2016
12
White matter tract abnormalities are associated with cognitive dysfunction in secondary progressive multiple sclerosis. ( 26733423 )
2016
13
Free serum haemoglobin is associated with brain atrophy in secondary progressive multiple sclerosis. ( 27996064 )
2016
14
Patterns of white matter damage are non-random and associated with cognitive function in secondary progressive multiple sclerosis. ( 27408797 )
2016
15
The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals. ( 27685028 )
2016
16
Secondary Progressive Multiple Sclerosis: Definition and Measurement. ( 27166830 )
2016
17
The role of MRI in the evaluation of secondary progressive multiple sclerosis. ( 26692498 )
2016
18
HIGH-DOSE BIOTIN TREATMENT FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS MAY INTERFERE WITH THYROID ASSAYS. ( 27917400 )
2016
19
Expression of DNA methylation genes in secondary progressive multiple sclerosis. ( 26711572 )
2016
20
Defining secondary progressive multiple sclerosis. ( 27401521 )
2016
21
iNKT Cells in Secondary Progressive Multiple Sclerosis Patients Display Pro-inflammatory Profiles. ( 27965675 )
2016
22
Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis. ( 27620894 )
2016
23
The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple Sclerosis. ( 27513853 )
2016
24
Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients. ( 27919195 )
2016
25
Identification of galectin-3 as a possible antibody target for secondary progressive multiple sclerosis. ( 27339072 )
2016
26
The Transition to Secondary Progressive Multiple Sclerosis: An Exploratory Qualitative Study of Health Professionals' Experiences. ( 27803641 )
2016
27
The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. ( 27003945 )
2016
28
Next-generation sequencing reveals broad down-regulation of microRNAs in secondary progressive multiple sclerosis CD4+ T cells. ( 27570566 )
2016
29
Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis. ( 26943957 )
2016
30
Measuring the Impact of Secondary Progressive Multiple Sclerosis (Spms) in the Ascend Trial: Equating the Msis-29, Msws-12, Abilhand-56 and Sf-36. ( 26533994 )
2015
31
Beta-interferon exposure and onset of secondary progressive multiple sclerosis. ( 25846809 )
2015
32
Reduced Voluntary Activation During Brief and Sustained Contractions of a Hand Muscle in Secondary-Progressive Multiple Sclerosis Patients. ( 26156191 )
2015
33
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. ( 26009563 )
2015
34
Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective interventions for secondary progressive multiple sclerosis. ( 25856304 )
2015
35
'You are just left to get on with it': qualitative study of patient and carer experiences of the transition to secondary progressive multiple sclerosis. ( 26201723 )
2015
36
A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis. ( 25595252 )
2015
37
A 10-year follow-up of the European multicenter trial of interferon I^-1b in secondary-progressive multiple sclerosis. ( 26362898 )
2015
38
Cortical sources of resting state electroencephalographic rhythms differ in relapsing-remitting and secondary progressive multiple sclerosis. ( 26111485 )
2015
39
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis. ( 26589141 )
2015
40
Motor cortex rTMS improves dexterity in relapsing-remitting and secondary progressive multiple sclerosis. ( 26358951 )
2015
41
A low vitamin D status at diagnosis is associated with an early conversion to secondary progressive multiple sclerosis. ( 26598277 )
2015
42
Characteristics of lesional and extra-lesional cortical grey matter in relapsing-remitting and secondary progressive multiple sclerosis: A magnetisation transfer and diffusion tensor imaging study. ( 26014608 )
2015
43
Brainstem glioblastoma in a patient with secondary progressive multiple sclerosis. ( 25990103 )
2015
44
Modeling The Natural History of Secondary-Progressive Multiple Sclerosis: A New Modeling Approach Using Discrete Event Simulation. ( 26533922 )
2015
45
Development of A Screening Tool to Support Identification of Patients With Secondary Progressive Multiple Sclerosis (Spms). ( 26534272 )
2015
46
Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. ( 26073484 )
2015
47
Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial. ( 26566454 )
2015
48
A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. ( 25253748 )
2014
49
Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. ( 24655729 )
2014
50
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier. ( 24686948 )
2014

Variations for Secondary Progressive Multiple Sclerosis

ClinVar genetic disease variations for Secondary Progressive Multiple Sclerosis:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> C (p.Phe273Leu) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
2 HNRNPA1 NM_002136.3(HNRNPA1): c.817T> G (p.Phe273Val) single nucleotide variant Pathogenic rs483353028 GRCh37 Chromosome 12, 54677661: 54677661
3 HNRNPA1 NM_002136.3(HNRNPA1): c.841T> C (p.Phe281Leu) single nucleotide variant Pathogenic rs483353031 GRCh37 Chromosome 12, 54677685: 54677685

Expression for Secondary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Secondary Progressive Multiple Sclerosis.

Pathways for Secondary Progressive Multiple Sclerosis

Pathways related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 44)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CCL2 CCR2 CCR5 CD40LG CXCL10 IFNB1
2
Show member pathways
13.79 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
3
Show member pathways
13.48 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
4
Show member pathways
13.35 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
5
Show member pathways
13.31 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
6
Show member pathways
13.19 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
7
Show member pathways
13.07 CCL2 CCR2 CCR5 CD40LG CXCL10 IFNB1
8
Show member pathways
12.87 CCL2 CXCL10 IFNB1 IFNG IL10 MMP9
9
Show member pathways
12.82 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
10
Show member pathways
12.75 CCL2 CXCL10 IFNB1 IFNG IL4
11
Show member pathways
12.55 CD40LG IFNG IL10 IL4
12
Show member pathways
12.39 CCR5 CD40LG IFNG IL10 IL4
13 12.36 CCL2 CCR2 CD40LG CXCL10 IFNG IL10
14
Show member pathways
12.29 CCL2 CXCL10 IFNG IL4 MMP9
15
Show member pathways
12.22 CCR5 CD40LG IFNG IL10 IL4
16
Show member pathways
12.18 IFNB1 IFNG IL10 IL4
17
Show member pathways
12.16 CXCL10 IFNB1 IFNG IL4
18
Show member pathways
12.13 IFNB1 IFNG IL10 IL4
19 12.01 CCL2 IFNG MMP9
20 11.97 CCR3 IFNG IL10 IL4
21 11.96 CCL2 IL10 IL4 MMP9
22
Show member pathways
11.92 CCR5 IFNG IL4
23 11.89 CCL2 CXCL10 MMP9
24 11.77 CXCR3 IFNG IL10 IL4
25
Show member pathways
11.74 CD40LG IFNG IL4
26 11.74 IFNB1 IFNG IL10
27
Show member pathways
11.72 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
28 11.7 CD40LG IL10 IL4
29 11.67 IFNB1 IFNG IL10
30 11.63 CD40LG IL10 IL4
31
Show member pathways
11.63 CD40LG IFNG MMP9
32 11.58 CCL2 CCR2 CXCL10 IFNG IL4 MBP
33 11.57 CCL2 CCR2 CCR3 IL4 MMP9
34 11.52 CCL2 CD40LG IFNG IL10
35 11.51 CCL2 CCR2 IFNG
36 11.49 IFNG IL10 IL4
37 11.38 CXCL10 IFNB1 IFNG
38 11.34 CCL2 CCR2 CD40LG MMP9
39 11.32 CD40LG IFNG IL4
40 11.23 IFNB1 IFNG IL10 IL4
41 11.17 IFNG IL10 IL4
42 11.16 CCL2 CD40LG CXCL10 IL10 IL4
43 11.13 CCL2 CCR3 IFNG MMP9
44 10.79 CCL2 CCR2 CCR5 CXCL10 IL10 IL4

GO Terms for Secondary Progressive Multiple Sclerosis

Cellular components related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.81 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10
2 neuronal cell body GO:0043025 9.62 CCL2 CCR2 MBP S100B
3 extracellular space GO:0005615 9.61 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10
4 perikaryon GO:0043204 9.43 CCL2 CCR2 IFNG
5 external side of plasma membrane GO:0009897 9.1 CCR5 CD40LG CXCL10 CXCR3 IFNG IL4

Biological processes related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 36)
id Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 CCL2 IFNG IL10 IL4
2 inflammatory response GO:0006954 9.86 CCL2 CCR2 CCR3 CCR5 CD40LG CXCL10
3 response to virus GO:0009615 9.83 CXCL10 IFNB1 IFNG
4 positive regulation of cytosolic calcium ion concentration GO:0007204 9.83 CCR2 CCR3 CCR5 CXCR3
5 cell surface receptor signaling pathway GO:0007166 9.8 CCL2 CCR5 CXCL10 CXCR3 IFNB1 IFNG
6 response to glucocorticoid GO:0051384 9.78 CCL2 IL10 S100B
7 positive regulation of endothelial cell proliferation GO:0001938 9.77 CCL2 CCR3 IL10
8 negative regulation of angiogenesis GO:0016525 9.77 CCL2 CCR2 CXCL10
9 cellular response to lipopolysaccharide GO:0071222 9.77 CCL2 CCR5 CXCL10 IFNG IL10
10 positive regulation of T cell proliferation GO:0042102 9.76 CD40LG IFNG IL4
11 B cell differentiation GO:0030183 9.76 CD40LG IFNB1 IL10 IL4
12 humoral immune response GO:0006959 9.74 CCL2 IFNB1 IFNG
13 cellular defense response GO:0006968 9.73 CCR2 CCR3 CCR5 IL4
14 B cell proliferation GO:0042100 9.69 CD40LG IFNB1 IL10
15 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.67 IFNB1 IFNG
16 positive regulation of synaptic transmission GO:0050806 9.67 CCL2 S100B
17 defense response to protozoan GO:0042832 9.67 IFNG IL10 IL4
18 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.66 IL10 MMP9
19 dendritic cell chemotaxis GO:0002407 9.66 CCR2 CCR5
20 negative regulation of growth of symbiont in host GO:0044130 9.65 IFNG IL10
21 positive regulation of monocyte chemotaxis GO:0090026 9.65 CCL2 CCR2 CXCL10
22 cellular homeostasis GO:0019725 9.64 CCL2 CCR2
23 negative regulation of nitric oxide biosynthetic process GO:0045019 9.64 IL10 IL4
24 positive regulation of chemokine biosynthetic process GO:0045080 9.63 IFNG IL4
25 positive regulation of isotype switching to IgG isotypes GO:0048304 9.63 IFNG IL4
26 chemokine-mediated signaling pathway GO:0070098 9.63 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
27 T cell chemotaxis GO:0010818 9.62 CXCL10 CXCR3
28 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.61 IL10 MBP
29 type 2 immune response GO:0042092 9.58 IL10 IL4
30 positive regulation of MHC class II biosynthetic process GO:0045348 9.58 IFNG IL10 IL4
31 regulation of vascular endothelial growth factor production GO:0010574 9.56 CCL2 CCR2
32 regulation of isotype switching GO:0045191 9.55 IL10 IL4
33 positive regulation of immune complex clearance by monocytes and macrophages GO:0090265 9.54 CCL2 CCR2
34 chemotaxis GO:0006935 9.5 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3
35 immune response GO:0006955 9.28 CCL2 CCR2 CCR5 CD40LG CXCL10 IFNG
36 G-protein coupled receptor signaling pathway GO:0007186 10.09 CCL2 CCR2 CCR3 CCR5 CXCL10 CXCR3

Molecular functions related to Secondary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 C-C chemokine receptor activity GO:0016493 9.33 CCR2 CCR3 CCR5
2 C-C chemokine binding GO:0019957 9.32 CCR3 CCR5
3 CCR2 chemokine receptor binding GO:0031727 9.26 CCL2 CCR2
4 chemokine receptor activity GO:0004950 9.26 CCR2 CCR3 CCR5 CXCR3
5 cytokine activity GO:0005125 9.17 CCL2 CD40LG CXCL10 IFNB1 IFNG IL10

Sources for Secondary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....